DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 2 Listed Suppliers

2 API Suppliers
2 Listed Suppliers

DEVELOPMENTS

13 Drugs in Development

13 Drugs in Development

FINISHED DOSAGE FORMULATIONS

4 FDF Dossiers, 2 FDA Orange Book, 2 Canada

4 FDF Dossiers
2 FDA Orange Book
2 Canada

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 1 STOCK RECAP #PipelineProspector, 16 NEWS #PharmaBuzz

media
2 DATA COMPILATION #PharmaFlow
1 STOCK RECAP #PipelineProspector
16 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 Annual Reports

globalSalesInformation
1 Annual Reports

PATENTS & EXCLUSIVITIES

16 US Patents, 2 US Exclusivities

patents
16 US Patents
2 US Exclusivities

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

13DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Azd5363, 1143532-39-1, Azd-5363, Azd 5363, (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

Molecular Formula

C₂₁H₂₅ClN₆O₂

Molecular Weight

428.9 g/mol

InChI Key

JDUBGYFRJFOXQC-KRWDZBQOSA-N

FDA UNII

WFR23M21IE

Capivasertib is a novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.

1 2D Structure

Capivasertib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

2.1.2 InChI

InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1

2.1.3 InChI Key

JDUBGYFRJFOXQC-KRWDZBQOSA-N

2.1.4 Canonical SMILES

C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4

2.1.5 Isomeric SMILES

C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4

2.2 Other Identifiers

2.2.1 UNII

WFR23M21IE

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide

2. Azd5363

2.3.2 Depositor-Supplied Synonyms

1. Azd5363

2. 1143532-39-1

3. Azd-5363

4. Azd 5363

5. (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

6. 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

7. Wfr23m21ie

8. 4-piperidinecarboxamide, 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-

9. 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinecarboxamide

10. Unii-wfr23m21ie

11. Chembl2325741

12. Cc-638

13. Capivasertib?

14. 4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide

15. 4-piperidinecarboxamide, 4-amino-n-((1s)-1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-

16. Capivasertib (jan/usan)

17. Capivasertib [inn]

18. Capivasertib [jan]

19. Capivasertib [usan]

20. Capivasertib (azd5363)

21. Mls006011179

22. Capivasertib [who-dd]

23. Schembl390243

24. Gtpl7709

25. Azc5363

26. Dtxsid40150710

27. Ex-a285

28. Us10654855, Example 9

29. Bdbm443385

30. Mfcd22628785

31. Nsc764039

32. Nsc782347

33. Nsc799347

34. S8019

35. Zinc43204023

36. Akos027323693

37. Bcp9000365

38. Ccg-268989

39. Cs-1284

40. Db12218

41. Nsc-764039

42. Nsc-782347

43. Nsc-799347

44. Ncgc00345795-01

45. Ncgc00345795-04

46. Ac-32685

47. Hy-15431

48. Smr004702948

49. Bcp0726000111

50. A1387

51. Sw220158-1

52. D11371

53. J-514447

54. Q27074756

55. 0xz

56. 4-amino-n-((1s)-1-(4-chlorophenyl)-3-hydroxypropyl)-1- (1h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide

57. Alternative Route 1: (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

2.4 Create Date

2009-04-28

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₂₅ClN₆O₂
Molecular Weight	428.9 g/mol
XLogP3	1.7
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	6
Exact Mass	428.1727518 g/mol
Monoisotopic Mass	428.1727518 g/mol
Topological Polar Surface Area	120 Å²
Heavy Atom Count	30
Formal Charge	0
Complexity	580
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Treatment of breast cancer , Treatment of prostate cancer

API SUPPLIERS

01

Chongqing Sintaho Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Medlab Asia & Asia Health

Not Confirmed

Chongqing Sintaho Pharma: A trusted partner globally for chemosynthetic APIs.

Contact Supplier

China

Virtual Booth

Digital Content

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT

Corporate PDF

02

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

CPhI WW Frankfurt

Booth #6.1A32

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

01

Chongqing Sintaho Pharmaceutical

China

Medlab Asia & Asia Health

Not Confirmed

Chongqing Sintaho Pharma: A trusted partner globally for chemosynthetic APIs.

Contact Supplier

China

Virtual Booth

Digital Content

Capivasertib

About the Company : Sintaho Pharmaceutical Co., Ltd., located in Chongqing, China, contributes to being the most dependable partner for global pharmaceutical companies. Sintaho specializes in chemosyn...

Sintaho Pharmaceutical Co., Ltd., located in Chongqing, China, contributes to being the most dependable partner for global pharmaceutical companies. Sintaho specializes in chemosynthetic APIs (application contains oncology, nervous system, and metabolic diseases and etc.,) with a product portfolio ranging from small molecule APIs, ADC compounds (linkers and payloads) to polypeptides, also provides CDMO services of cytotoxic and OEB4/5 grade APIs.

Corporate PDF